Treatment with Anakinra, a recombinant IL-1 receptor antagonist, unlikely to induce lasting remission in patients with CGD colitis

American Journal of Gastroenterology

Volumn 110, Issue 6, 2015, Pages 938-939

  Hahn, Katherine J ^a   Ho, Nancy ^b   Yockey, Lynne ^c   Kreuzberg, Samantha ^b   Daub, Janine ^c   Rump, Amy ^c   Marciano, Beatriz E ^c   Quezado, Martha ^d   Malech, Harry L ^e   Holland, Steven M ^c   Heller, Theo ^b   Zerbe, Christa S ^c  

^a GEORGETOWN UNIVERSITY   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; IMMUNOMODULATING AGENT; INTERLEUKIN 1BETA; REACTIVE OXYGEN METABOLITE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; ANTIRHEUMATIC AGENT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ABDOMINAL PAIN; ABSCESS; ADOLESCENT; ADULT; ANUS FISTULA; CHILD; CHRONIC GRANULOMATOUS DISEASE; CLINICAL ARTICLE; COLITIS; CORTICOSTEROID THERAPY; DIARRHEA; DRUG MEGADOSE; HUMAN; LETTER; LOW DRUG DOSE; MELENA; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; COMPLICATION; FEMALE; GRANULOMATOUS DISEASE, CHRONIC; MAINTENANCE CHEMOTHERAPY; MALE; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIRHEUMATIC AGENTS; CHILD; COLITIS; FEMALE; GRANULOMATOUS DISEASE, CHRONIC; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MAINTENANCE CHEMOTHERAPY; MALE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84930738919     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2015.135     Document Type: Letter

References (7)

1. Marciano BE, Rosenzweig SD, Keliner DE et al. Gastrointestinal involvement in chronic granulomatous disease. Pediatrics 2004;114: 462-7.
2. Alimchandani M, Lai JP, Aung PP et al. Gastrointestinal histopathology in chronic granulomatous disease: a study of 87 patients. Am J Surg Pathol 2013;37: 1365-72.
3. Uzel G, Orange JS, Poliak N et al. Complications of tumor necrosis factor-blockade in chronic granulomatous disease-related colitis. Clin Infect Dis 2010;51: 1429-34.
4. De Luca A, Smeeken SP, Casagrande A et al. IL-1 receptor blockade restores autophagy and reduces inflammation in chronic granulomatous disease in mice and in humans. Proc Natl Acad Sci USA 2014;111: 3526-31.
5. Harvey RF, Bradsaw JM. A simple index of Crohn's disease activity. Lancet 1980;1: 514.
6. Winkelstein JA, Marino MC, Johnston RB et al. Chronic granulomatous disease: report on a National Registry of 368 Patients. Medicine 2000;79: 155-69.
7. Kuhns DB, Alvord WG, Heller T et al. Residual NADPH oxidase and survival in chronic granulomatous disease. N Engl J Med 2010;363: 2600-10.